Dianthus Therapeutics, Inc.: T. Rowe Price Investment Management, Inc. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
T. Rowe Price Investment Management amended its Schedule 13G filing on Dianthus Therapeutics, disclosing a change in its passive stake in the clinical-stage biotech. The update was filed with the SEC under accession number 0001897612-26-000744, though the filing summary did not specify the revised share count or percentage held. Schedule 13G amendments are typically triggered when an institutional holder's position crosses or moves past the 5% reporting threshold, making the disclosure a signal of shifting institutional ownership in the small-cap name. Investors will watch for the full filing details to confirm whether T. Rowe Price increased or trimmed its position, and for any subsequent 13F or insider disclosures that clarify the direction of institutional flows.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Dianthus Therapeutics, Inc., T. Rowe Price Investment Management, Inc.